← All trials
NCT04775797
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 25, 2021
- Primary completion
- Apr 30, 2022
- Completion date
- Aug 31, 2022
- First posted
- Mar 1, 2021
- Last posted
- Jul 14, 2021
- Enrollment
- 60
- Arms / groups
- 5 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Arbutus Biopharma CorporationLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.